Patents Examined by Sergio Coffa
  • Use of recombinant human secretory DDRGK1
    Patent number: 11560411
    Abstract: The present disclosure provides the use of a recombinant human secretory DDRGK1. Experiments demonstrate that the recombinant human secretory DDRGK1 prepared by the present disclosure can be used in the preparation of biological medicines for treating intervertebral disc degeneration, fractures or bone defects. The recombinant human secretory DDRGK1 of the present disclosure provides a promising direction for the treatment of bone related diseases and has obtained firm scientific evidence, thereby expanding the further application of recombinant human secretory DDRGK1 in clinical practice.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 24, 2023
    Assignee: SHANGHAI NINTH PEOPLE'S HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Tangjun Zhou, Ying Xia, Xiao Yang, An Qin, Yu Cao, Jie Zhao
  • Method of treating inflammatory bowel disease
    Patent number: 11535655
    Abstract: Provided herein is a method for treating an inflammatory bowel disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hemoglobin to the subject.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: December 27, 2022
    Assignee: Cheer Global Limited
    Inventors: Sui Yi Kwok, Norman Fung Man Wai, Chi Shing Tai
  • Calcium indicator polypeptides and methods of use thereof
    Patent number: 11531035
    Abstract: The present disclosure provides a genetically encoded calcium indicator (GECI), nucleic acids encoding the GECI, and host cells comprising the GECI. The present disclosure also provides methods of detecting a change in the intracellular concentration of a cell expressing a GECI of the present disclosure.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: December 20, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl A. Deisseroth, Charu Ramakrishnan, Masatoshi Inoue
  • Cyclic polypeptides for PCSK9 inhibition
    Patent number: 11530244
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 20, 2022
    Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
  • Macrocyclic polypeptides
    Patent number: 11524979
    Abstract: Disclosed herein are macrocyclic polypeptides having no more than 3 ammo acid substitutions compared to the amino acid sequence of any one of SEQ ID NO: 1-2.37 or a mirror image thereof, wherein the polypeptide includes both L and D amino acids, libraries of such polypeptides, and uses thereof.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: December 13, 2022
    Assignee: University of Washington
    Inventors: Parisa Hosseinzadeh, David Baker, Gaurav Bhardwaj, Vikram K. Mulligan
  • Formulations and methods of use for alpha connexin c-terminal (ACT) peptides
    Patent number: 11524049
    Abstract: This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: December 13, 2022
    Assignee: XEQUEL BIO, INC.
    Inventor: Gautam Ghatnekar
  • Synthesis of echinocandin antifungal agent
    Patent number: 11524980
    Abstract: The present invention relates to echinocandin cyclopeptides and to methods for preparing echinocandin cyclopeptides.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: December 13, 2022
    Assignee: Cidara Therapeutics, Inc.
    Inventors: David Hughes, Martin Patrick Hughes, Robert Michael Hughes, Balasingam Radhakrishnan, Yannick Borguet, Steven McIntyre
  • Orally active, cell-penetrating homing peptide and methods using same
    Patent number: 11524077
    Abstract: Disclosed are compositions and methods useful for oral delivery of targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. The disclosed targeting is useful for oral delivery of therapeutic and detectable agents to diseased tissue in an animal.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: December 13, 2022
    Assignee: Vascular BioSciences
    Inventor: David Mann
  • Macrocyclic peptides to decrease c-Myc protein levels and reduce cancer cell growth
    Patent number: 11510964
    Abstract: The present technology provides methods end medicaments useful for treating prostate cancer and breast cancer. Such methods include administering at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo[Phe-D-Pro-Phe-D-Trp] to a subject suffering from prostate cancer or breast cancer.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: November 29, 2022
    Assignees: UNIVERSITY OF KANSAS, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Jane Aldrich, Archana Mukhopadhyay, Laura E. Hanold
  • Method for removing water from compound solution and performing conjugate acid conversion
    Patent number: 11512123
    Abstract: The present invention relates to a method for removing water from a compound solution and performing conjugate acid conversion. The method uses a nanometer film to perform reverse osmosis for the compound solution to remove water, and provides a conjugate acid to replace the acidic substances in the compound solution in order to obtain compound conjugate acid salts. The method of the present invention can effectively reduce the water content of the compound solution and replace the conjugate acid of the compound to form the desired compound conjugate acid salt.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: November 29, 2022
    Assignee: CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD.
    Inventors: Yao-Lung Hsu, Kuang-Chan Hsieh, Hui-Wen Cheng, Zong-Han Yang
  • Cyclic polypeptides for PCSK9 inhibition
    Patent number: 11505575
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 22, 2022
    Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
  • CCN3 and CCN3 peptides and analogs thereof for therapeutic use
    Patent number: 11505582
    Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: November 22, 2022
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Bruce L. Riser
  • Antibacterial protein EFAL-2 having bacteriolytic ability with respect to
    Patent number: 11492378
    Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP), which has the ability to kill Enterococcus faecium and an amino acid sequence represented by SEQ ID NO: 2, a pharmaceutical composition containing the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium using the pharmaceutical composition.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: November 8, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang
  • Treatment of abnormal cutaneous scarring
    Patent number: 11491214
    Abstract: The invention relates to the prevention and treatment of pathologic scars using APC or analogue thereof.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: November 8, 2022
    Assignee: ZZ BIOTECH LLC
    Inventors: Christopher John Jackson, Meilang Xue
  • Synergistic composition of a nematicide
    Patent number: 11484035
    Abstract: The present invention provides a synergistic composition of a nematicide comprising of a nematicidal peptides derived from CED-4 protein sequence comprising of at least two peptides. The nematicidal peptides individually show 100% nematicidal activity at a concentration of 1 mg/ml, whereas, the combination of at least two peptides in a ratio of 1:1 shows 100% nematicidal activity at concentration as low as 0.8 mg/ml bringing a synergistic effect. This synergistic nematicidal composition is highly economical as it requires 20% less peptide concentration for 100% activity, moreover the composition is environmentally safe and non-toxic to humans and animals.
    Type: Grant
    Filed: March 17, 2018
    Date of Patent: November 1, 2022
    Assignee: TELLURIS BIOTECH INDIA PRIVATE LIMITED
    Inventors: Venu Polineni, Alejandro Calderón Urrea, Glenda W. Polack
  • Methods for treating HCV
    Patent number: 11484534
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 1, 2022
    Assignee: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Tianli Wang
  • Compositions and methods for inhibition of L-plastin activity in osteoclasts to reduce bone loss
    Patent number: 11485762
    Abstract: The present disclosure relates to compositions and methods for inhibiting L-plastin activity for inhibiting bone resorption activity of osteoclasts. In certain instances, the compositions and methods are used to treat or prevent a disease or disorder associated with bone resorption. In one aspect, the compositions and methods relate to peptide inhibitors comprising an N-terminal fragment of L-plastin.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: November 1, 2022
    Assignee: University of Maryland, Baltimore
    Inventor: Meenakshi Chellaiah
  • Inhibitors of metastasis
    Patent number: 11466054
    Abstract: The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: October 11, 2022
    Assignees: BIOMARCK PHARMACEUTICALS LTD., NORTH CAROLINA STATE UNIVERSITY
    Inventors: Indu Parikh, Kenneth B. Adler
  • Antigen capturing nanoparticles for use in cancer immunotherapy
    Patent number: 11446390
    Abstract: Disclosed herein are antigen-capturing nanoparticles. Specifically, the subject matter contained herein pertains to novel nanoparticles that can capture a multitude of tumor antigens that are released from tumor cells. Also, provided herein are methods for preparing the antigen-capturing nanoparticles and methods for the treatment of disease in a subject comprising administering the antigen-capturing nanoparticles.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: September 20, 2022
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Andrew Wang, Yuanzeng Min, Zach Rodgers
  • Synthetic platelets
    Patent number: 11439688
    Abstract: A synthetic platelet including a biocompatible flexible nanoparticle, the nanoparticle having an outer surface and a plurality of site targeted peptides conjugated to the surface, the synthetic platelet also including a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: September 13, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Anirban Sen Gupta, Christa Pawloski